The City Council unanimously voted to ban the use of a class of rat poisons known as second-generation anticoagulant rodenticides, or SGARs, on city-owned property after a public hearing ...

The body does not absorb berberine well, limiting its ability to affect body weight significantly. However, berberine may ...

BMS acquired Cobenfy as part of its $14 billion takeover of Karuna Therapeutics towards the end of 2023, and analysts at ...

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in licensing deals, on average, than in 2023 with an eye toward enriching their ...

Cadrenal Therapeutics, Inc. , a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapies, leading with tecarfarin, a new Vitamin K antagonist will ...

During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed the data supporting the 2 newer BTK ...

Bristol-Myers Squibb (NYSE:BMY), a global biopharmaceutical giant with a market capitalization of $120.8 billion, finds ...

Patients on oral anticoagulants or antiplatelet agents showed no meaningful difference in detection rates. Oral anticoagulant or antiplatelet medication use had no substantial effect on the ...

“Studies have shown that healthcare utilization at the end of life is high, and patients receive aggressive medical care that ...

Rodman & Renshaw initiated coverage on shares of biopharmaceutical company Talphera (NASDAQ: TLPH) with a Buy rating and a price target of $4.00. The firm's analysts highlighted Talphera's focus on ...

Despite California's statewide bans on toxic mouse and rat poison use, traces of these poisons are still being found in non-target wildlife species ... at least three were found to be exposed to ...

Factor XI has emerged as a target for anticoagulants that have the potential to be safer than currently available agents because there is mounting evidence that factor XI is essential for ...